en.wikipedia.org website review
Improve your SEO :: free trial!
en.wikipedia.org is 53% geoptimaliseerd!
SEO Keyword summary for en.wikipedia.org/wiki/phosphoinositide_3-kinase_inhibitor
Keywords are extracted from the main content of your website and are the primary indicator of the words this page could rank for. By frequenty count we expect your focus keyword to be with
Focus keyword
Short and long tail
Short Tail Keywords with phase trial |
long Tail Keywords (2 words) clinical trial trial number clinical trials clinicaltrialsgov clinical phase iii |
long Tail Keywords (3 words) clinical trial number clinicaltrialsgov clinical trial search for phase phase iii trial 2 clinical trials phase 2 clinical pan-class i pi3k |
en.wikipedia.org On-Page SEO Scan
Descriptive Elements
The <head> element of a en.wikipedia.org/wiki/phosphoinositide_3-kinase_inhibitor page is used to inform the browser and visitors of the page about the general meta information. The head section of the page is where we place the page title, the definition of the HTML version used, the language of in which the page is written. In the head section we can also include JavaScript and CSS (markup) files for the page.
Page title
Title length
phosphoinositide kinase inhibitor wikipedia
Meta description
Meta description legth
Meta description SEO
No meta relevance in the description detected !
Content SEO
Number of Words
Spam detected?
Headings
Heading distribution
Heading normalisation
Heading SEO impact
Emphasis (bold and italic)
Emphasis SEO impact
Images
Number of images
Images dimensions
Image alt descriptions
Images SEO impact
wikipedia free encyclopedia public domain wikimedia foundation powered mediawiki
Mobile SEO en.wikipedia.org/wiki/phosphoinositide_3-kinase_inhibitor
Mobile rendering
Mobile optimizations
Responsive design detected (mobile css)
No flash detected !
Mobile improvement
Marketing / lead generation for en.wikipedia.org/wiki/phosphoinositide_3-kinase_inhibitor
Social Media
Facebook shares | Facebook likes | ||
Facebook comments | Tweets | ||
Google +1 |
Conversion form
Search form
Analytics
Online presence
SERP Preview
SERP Title
SERP Link
SERP Description
Domain Level SEO
Domain name
16 characters long
Domain name SEO Impact
Path name
-kinase found in path !
inhibitor found in path !
Structured data
Publisher Markup
Other Structured data
Website configuration
Correct processing of non-existing pages?
Favicon icon found?
Robots.txt found?
Sitemap found?
Navigation and internal links
Navigation
Url seperator
Human readable urls
Number of links
Link SEO Impact
statistics
|
en.m.wikipedia.org |
en.wikipedia.org wikimedia foundation inc
|
w httpsenwikipediaorgwindexphptitlephosphoinositide3kinaseinhibitoroldid1235553368
page information
printable version
fimepinostat
sitimagene ceradenovec
|
wiki pi3kaktmtor pathway
copanlisib
idelalisib
mtor
dactolisib
rigosertib
signal pathway
targeted therapy
isoforms
class 1 pi3ks
p110 alpha
p110 beta
p110 gamma
p110pharmacology
pten
inflammatory respiratory disease
aging
trade name
food and drug administration
rituximab
follicular lymphoma
duvelisib
alpelisib
fulvestrant
umbralisib
csnk1e
marginal zone lymphoma
leniolisib
activated pi3k delta syndrome
pasli disease
phase iii clinical trials
buparlisib
paclitaxel
head and neck
squamous cell carcinoma
progressionfree survival
novartis
nonhodgkin lymphoma
rchop
placebocontrolled
respiratory illness
ofatumumab
bendamustine
pivotal trial
parsaclisib
mantle cell lymphoma
myelofibrosis
warm antibody autoimmune hemolytic anemia
glioblastoma
taselisib
zandelisib
inavolisib
phase ii clinical trials
brainpermeant
eganelisib
hdac inhibitor
diffuse large bcell lymphoma
gedatolisib
lymphoma
pictilisib
dnapk
sjgren syndrome
renal cell carcinoma
endometrial cancer
sonolisib
wortmannin
voxtalisib
amg 319
integrin receptors
ly294002
pmid
s2cid
public domain
clinicaltrialsgov
chemotherapeutic agents
antineoplastic agents
l01
sps
m phase
microtubule
vinca alkaloids
vinblastine
vincristine
vindesine
vinflunine
vinorelbine
taxanes
cabazitaxel
docetaxel
larotaxel
ortataxel
tesetaxel
epothilones
ixabepilone
dna replication
antimetabolites
s phase
folic acid
dihydrofolate reductase inhibitor
aminopterin
methotrexate
pemetrexed
pralatrexate
thymidylate synthase inhibitor
raltitrexed
purine
adenosine deaminase inhibitor
pentostatin
halogenated
ribonucleotide reductase inhibitor
cladribine
clofarabine
fludarabine
nelarabine
rabacfosadine
thiopurine
mercaptopurine
tioguanine
pyrimidine
capecitabine
carmofur
doxifluridine
floxuridine
fluorouracil
tegafur
gimeraciloteracil
dna polymerase inhibitor
cytarabine
cytarabine
gemcitabine
hypomethylating agent
azacitidine
decitabine
deoxyribonucleotide
hydroxycarbamide
topoisomerase inhibitors
camptotheca
belotecan
camptothecin
etirinotecan pegol
exatecan
irinotecan
lurtotecan
rubitecan
topotecan
podophyllum
etoposide
teniposide
intercalation
anthracyclines
aclarubicin
amrubicin
daunorubicin
doxorubicin
epirubicin
idarubicin
pirarubicin
valrubicin
zorubicin
anthracenediones
losoxantrone
mitoxantrone
pixantrone
amsacrine
bisantrene
crisnatol
menogaril
crosslinking of dna
nonclassical
nitrogen mustards
chlormethine
cyclophosphamide
ifosfamide
trofosfamide
chlorambucil
melphalan
melphalan flufenamide
prednimustine
uramustine
nitrosoureas
carmustine
fotemustine
lomustine
semustine
nimustine
ranimustine
streptozocin
alkyl sulfonates
busulfan
mannosulfan
treosulfan
aziridines
carboquone
thiotepa
triaziquone
triethylenemelamine
platinumbased
carboplatin
cisplatin
dicycloplatin
nedaplatin
oxaliplatin
satraplatin
altretamine
hydrazines
procarbazine
etoglucid
mitobronitol
pipobroman
triazenes
dacarbazine
mitozolomide
temozolomide
streptomyces
dactinomycin
bleomycin
mitomycins
plicamycin
photosensitizers
aminolevulinic acid
efaproxiral
methyl aminolevulinate
padeliporfin
porphyrin derivatives
porfimer sodium
talaporfin
temoporfin
verteporfin
enzyme inhibitors
tipifarnib
inhibitors
abemaciclib
alvocidib
palbociclib
ribociclib
seliciclib
bortezomib
carfilzomib
oprozomib
ixazomib
anagrelide
impdi
tiazofurin
masoprocol
parp inhibitor
fuzuloparib
niraparib
abiraterone acetate
olaparib
rucaparib
belinostat
entinostat
panobinostat
romidepsin
vorinostat
receptor antagonists
atrasentan
retinoid x receptor
bexarotene
sex steroid
testolactone
adagrasib
aflibercept
arsenic trioxide
asparagine depleters
asparaginase
pegaspargase
axicabtagene ciloleucel
belzutifan
brexucabtagene autoleucel
celecoxib
ciltacabtagene autoleucel
demecolcine
denileukin diftitox
eflornithine
elesclomol
elsamitrucin
enasidenib
epacadostat
eribulin
estramustine
glasdegib
idecabtagene vicleucel
imetelstat
ivosidenib
lifileucel
lisocabtagene maraleucel
lonidamine
lucanthone
lurbinectedin
mitoguazone
mitotane
nadofaragene firadenovec
navitoclax
oblimersen
omacetaxine mepesuccinate
plitidepsin
tabelecleucel
retinoids
alitretinoin
tretinoin
selinexor
sotorasib
tagraxofusp
talimogene laherparepvec
tazemetostat
tebentafusp
tiazofurine
tigilanol tiglate
tisagenlecleucel
trabectedin
veliparib
venetoclax
vorasidenib
vosaroxin
withdrawn
clinical trials
phase iii
|
Links to external pages
Outloing links
sl.wikipedia.org
www.wikidata.org
www.wikidata.org
www.joenja.com
www.pharming.com
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
api.semanticscholar.org
www.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
api.semanticscholar.org
www.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.archive.today
www.doi.org
pubmed.ncbi.nlm.nih.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
wayback.archive-it.org
www.doi.org
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
api.semanticscholar.org
www.doi.org
pubmed.ncbi.nlm.nih.gov
api.semanticscholar.org
www.news-medical.net
pubmed.ncbi.nlm.nih.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
www.fda.gov
www.clinicaltrials.gov
www.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.clinicaltrials.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
www.clinicaltrials.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
api.semanticscholar.org
www.clinicaltrials.gov
www.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.clinicaltrials.gov
www.doi.org
api.semanticscholar.org
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.endpts.com
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.cancertherapyadvisor.com
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.clinicaltrials.gov
www.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
www.ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov
www.doi.org
pubmed.ncbi.nlm.nih.gov
web.archive.org
foundation.wikimedia.org
foundation.wikimedia.org
www.wikimediafoundation.org
SEO Advice for en.wikipedia.org
In this section we provide pointers on how you can to optimize your web page so it can be found more easily by search engines and how to make it rank higher by optimizing the content of the page itself. For each of the individual criteria the maximum score is 100%. A score below 70% is considered to be indication that the page is not complying with general SEO standards and should be evaluated and/or fixed. Not every factor is weighted the same and some are not as important as others. Relatively unimportant factors like meta keywords are not included in the overall score.
Item | Factor | Pointers | |
---|---|---|---|
PageTitle | 100% | Far too many sites lack a page title. A page title is the first thing that shows in the search results so always use the title element. | |
Title relevance | 33% | A title should reflect the contents of a site. This site has a 25 % match | |
Title Length | 100% | Limit your title to anywhere between 40 and 70 characters. Your title was 48 characters long | |
Meta Description | 0% | A meta description is the second element that shows in the search results so always use the meta description. | |
Meta description length | 0% | The meta description should be between 145 and 160 characters. This meta description is 1 characters long. | |
Meta description relevance | 0% | Meta Description should reflect the contents of a site. This site has a 0 % match | |
Number of internal links | 30% | Linking to internal pages makes pages easier to find for search engines. Try to keep the number of links on your page roughly below 100. There are 565 internal links on this page. | |
Folder structure | 100% | We found a folder structure in the links on your page. A good folder structure makes a site easier to navigate. We found 3 level 1 folders and 10 folders above or in the first level of navigation. | |
Headings | 44% | Headers should reflect the contents of a site. This site has a 19 % match | |
Links | 8% | Link anchors should to some degree reflect the contents of a site. This site has a 4 % match | |
Image alt tags | 0% | Image alt tags should to some degree reflect the contents of a site. This site has a 0 % match | |
Bold and italic | 15% | Bold and italic tags should reflect the contents of a site to some degree. This site has a 5 % match | |
Html ratio | 60% | Try to keep the html / text ratio as low as possible. More html means longer loading times. Layout should be handled in a serpate css file | |
Image descriptions | 63% | 62.5 % of all images have been described via the "alt" attribute. Describing images with relevant text may lead to better results in the search engines. | |
Page errors | 100% | Pages with no errors display significantly faster on most browsers. We detected 0 errors and warnings | |
WordCount | 20% | An ideal page contains between 400 and 600 words.This page contains 5608 words | |
Server response time | 100% | A fast server speeds up a website. This server responds 93.15% faster then average | |
Gzip compression | 30% | This site does not use Gzip compression. Pages may not display as fast as they could | |
Keywords in Domainname | 30% | There are no important keywords in your domain name | |
Keywords in domain path | 100% | There are important keywords in the domain path | |
Structured Data | 100% | Structured data makes it easier for search engines to index your website | |
Inline css | 0% | Do not use inline css declarations. Inline css will slow down the rendering of the website. We detected 105 inline style declarations ( <a style="color:green">) with a size of 1639 bytes | |
Excessive use of the same words | 100% | There is no indication that there are one or more keywords that are used excessively. | |
Frames or iframes | 100% | Perfect, detected not (i)frames on your webpagina | |
Flash | 100% | Perfect, we detected no flash objects on your page | |
Css | 30% | We detected too much (2) CSS files on your page. Css files block the loading of a webpage. | |
Javascript | 100% | Perfect, we did not detect too many blocking JavaScript files | |
Mobile Website | 100% | Perfect, we found a responsive design for mobile users | |
Most important heading | 100% | Perfect, we detected a correct use of the most important (h1) heading! | |
Normalized headings | 40% | We dit not font a normalized heading structure. A heading 2 (h2) for example should be followed by a heading of an equal level (h2), a child heading (h3) or even a aprent heading (h1). |
How would you like to have SEO advice for all your pages ?? Start your SEO Dashboard and optimize your website!
en.wikipedia.org images and descriptions
8 images found at en.wikipedia.org Images can improve the user experience for a website by making a pag visually appealing Images can also add extra keyword relevance to a webpage by using alt tags. Images can also slow down a website. If the width and height for a picture is not specified for a browser know in advance how large the image is. A browser must first load the picture and see before it knows how much space should be on the page. Upon reservation In the meantime, the browser can do little but wait. When the height and width for the plate are given in the HTML code, a browser just continues to build for a page while the images load in the background.
http://en.wikipedia.org/static/images/icons/wikipedia.png height: 50 width: 50 description: no alt description found |
|
http://en.wikipedia.org/static/images/mobile/copyright/wikipedia-wordmark-en.svg height: height attribute not set width: width attribute not set description: wikipedia |
|
http://en.wikipedia.org/static/images/mobile/copyright/wikipedia-tagline-en.svg height: 13 width: 117 description: the free encyclopedia |
|
https://upload.wikimedia.org/wikipedia/commons/thumb/c/c7/pi3k_inhibitors_overview_mishra2021.jpg/400px-pi3k_inhibitors_overview_mishra2021.jpg height: 399 width: 400 description: no alt description found |
|
https://upload.wikimedia.org/wikipedia/en/thumb/6/62/pd-icon.svg/12px-pd-icon.svg.png height: 12 width: 12 description: public domain |
|
https://login.wikimedia.org/wiki/special:centralautologin/start?type=1x1 height: 1 width: 1 description: no alt description found |
|
http://en.wikipedia.org/static/images/footer/wikimedia-button.svg height: 29 width: 84 description: wikimedia foundation |
|
http://en.wikipedia.org/w/resources/assets/poweredby_mediawiki.svg height: 31 width: 88 description: powered by mediawiki |
How are images contributing to your SEO site-wise ? Your leading content tool has the awnsers!